Poseida Therapeutics, INC
Market Movers (8-K)
Poseida Therapeutics has been acquired by Roche Holdings, completing a merger, delisting from Nasdaq, and becoming a wholly-owned subsidiary.
Roche Holdings, Inc. has agreed to acquire Poseida Therapeutics for $9.00 per share in cash at closing, plus a contingent value right (CVR) of up to $4.00 per share, potentially valuing the deal at $1.5 billion.
Poseida Therapeutics shared updates on its allogeneic CAR-T therapy pipeline, including clinical and preclinical data across hematologic malignancies, autoimmune diseases, and solid tumors, during a virtual R&D Day.
Better than expected
Poseida Therapeutics announced positive Q3 2024 financial results, highlighted by significant collaboration revenue and promising clinical trial updates for its allogeneic CAR-T therapies.
Better than expected
Poseida Therapeutics reported a 91% overall response rate in a Phase 1 trial for its P-BCMA-ALLO1 therapy in heavily pretreated multiple myeloma patients, using an optimized lymphodepletion regimen.
Better than expected
Poseida Therapeutics reported strong progress in its allogeneic cell therapy and genetic medicine programs, highlighted by key partnership advancements and upcoming clinical data readouts.
Quarterly Earnings (10-Q)
10-Q: Poseida Therapeutics Reports Positive Cash Flow in Q3 2024 Amidst Strong Collaboration Revenue
Poseida Therapeutics reports a net loss of $35.4 million for the nine months ended September 30, 2024, but positive cash flow from operations of $13.7 million, driven by significant collaboration revenue.
Better than expected
Capital raise
Poseida Therapeutics reports a net loss of $55.6 million for the first half of 2024, but also positive cash flow from operations of $23.3 million, and highlights progress in its allogeneic CAR-T and genetic medicines programs.
Worse than expected
Capital raise
10-Q: Poseida Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
Poseida Therapeutics reports increased collaboration revenue and provides updates on its clinical programs in its first quarter 2024 financial results.
Capital raise
Annual Reports (10-K)
Poseida Therapeutics' 10-K filing highlights progress in its cell and gene therapy programs, including strategic collaborations and clinical trial advancements.
Capital raise
Better than expected
Insider Trading (Form 4)
A Form 4 filing reveals a Poseida Therapeutics director's disposition of shares and options following the company's merger with Roche, including cash and contingent value rights.
Following the merger of Poseida Therapeutics with Roche, a director, Luke Corning, disposed of shares and options as part of the merger agreement.
A Form 4 filing reveals a Poseida Therapeutics director's disposition of shares and options following the company's acquisition by Roche.
A Form 4 filing reveals a Poseida Therapeutics director's disposition of shares and options following the company's merger with Roche.
Following the completion of the merger with Roche, a Poseida Therapeutics director, Cynthia Collins, disposed of her shares and options, receiving cash and contingent value rights.
Following the completion of the merger with Roche, Poseida Therapeutics' CFO, Johanna Mylet, disposed of her shares and options as part of the acquisition agreement.